Sorafenib-Associated Facial Acneiform Eruption

Sorafenib, an oral multikinase inhibitor, was associated with facial acneiform eruptions in five patients, typically appearing after 4 weeks of treatment at a dose of 400 mg twice daily. The eruptions resembled chloracne in three patients and presented as papules and pustules in two others. Topical treatments provided partial improvement, but significant improvement or resolution occurred after reducing the dose or discontinuing sorafenib. This cutaneous adverse event was rare and observed in patients with various cancers, including liver epithelioid hemangioendothelioma, metastatic renal cell carcinoma, and hepatocellular carcinoma.